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ABSTRACT
Introduction The absence of a diagnostic test for 
acute rheumatic fever (ARF) is a major impediment in 
managing this serious childhood condition. ARF is an 
autoimmune condition triggered by infection with group 
A Streptococcus. It is the precursor to rheumatic heart 
disease (RHD), a leading cause of health inequity and 
premature mortality for Indigenous peoples of Australia, 
New Zealand and internationally.
Methods and analysis ‘Searching for a Technology- 
Driven Acute Rheumatic Fever Test’ (START) is a biomarker 
discovery study that aims to detect and test a biomarker 
signature that distinguishes ARF cases from non- ARF, and 
use systems biology and serology to better understand 
ARF pathogenesis. Eligible participants with ARF diagnosed 
by an expert clinical panel according to the 2015 Revised 
Jones Criteria, aged 5–30 years, will be recruited from 
three hospitals in Australia and New Zealand. Age, sex and 
ethnicity- matched individuals who are healthy or have 
non- ARF acute diagnoses or RHD, will be recruited as 
controls. In the discovery cohort, blood samples collected 
at baseline, and during convalescence in a subset, will 
be interrogated by comprehensive profiling to generate 
possible diagnostic biomarker signatures. A biomarker 
validation cohort will subsequently be used to test 
promising combinations of biomarkers. By defining the 
first biomarker signatures able to discriminate between 
ARF and other clinical conditions, the START study has the 
potential to transform the approach to ARF diagnosis and 
RHD prevention.
Ethics and dissemination The study has approval from 
the Northern Territory Department of Health and Menzies 
School of Health Research ethics committee and the New 
Zealand Health and Disability Ethics Committee. It will be 
conducted according to ethical standards for research 
involving Indigenous Australians and New Zealand 
Māori and Pacific Peoples. Indigenous investigators 
and governance groups will provide oversight of study 
processes and advise on cultural matters.
INTRODUCTION
The absence of a diagnostic test for acute 
rheumatic fever (ARF) is a major impediment 
to management and epidemiological under-
standing of this serious childhood condition. 
ARF is one of the best examples of human 
autoimmunity caused by an infection, with 
group A Streptococcus (GAS) the identified 
trigger. It is the precursor to rheumatic heart 
disease (RHD), a leading cause of health 
inequity and premature mortality for Indig-
enous peoples of Australia, New Zealand 
(NZ) and internationally.1 Prompt diagnosis 
of ARF allows timely commencement of 
secondary prophylaxis with long- acting peni-
cillin to prevent repeated GAS infections that 
drive ARF recurrences. ARF recurrences are 
in turn the main mechanism responsible for 
Strengths and limitations of this study
 ► Searching for a Technology- Driven Acute Rheumatic 
Fever Test addresses a critically important health 
problem, acute rheumatic fever (ARF), which dispro-
portionately affects global Indigenous populations 
and for which there is no diagnostic test nor effec-
tive treatment able to limit progression to rheumatic 
heart disease.
 ► The large sample size recruited across international 
sites and the use of unbiased, comprehensive im-
mune profiling will maximise the likelihood of being 
able to define a biomarker signature which can dis-
criminate between ARF and other clinical conditions.
 ► The most robust ‘gold- standard’ rheumatic fever 
diagnostic process currently available will be used, 
comprising the revised 2015 Jones Criteria applied 
by an expert clinical panel.
 ► Culturally safe processes with Indigenous gover-
nance guide the development and conduct of the 
study.
 ► An inherent limitation is heterogeneity among peo-
ple with ARF with regard to demographic factors, 
ARF type (first or recurrent), diagnostic category 
(possible, probable, definite), clinical phenotype 
(carditis, chorea, arthritis, skin and soft- tissue) and 
timing in relation to ARF onset (variable time taken 
for healthcare to be reached after disease onset, 
consent gained and blood samples collected).
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development of RHD. Underdiagnosis of ARF appears 
to be a major contributor to the high rates of RHD in 
Aboriginal communities in Australia’s Northern Terri-
tory (NT), where 76% of patients with RHD lack a prior 
ARF diagnosis.2 Similarly a cohort study in NZ found the 
majority of RHD cases (65%) had never been previously 
hospitalised with ARF.3 Similar findings are reported in 
African countries.4
The Jones criteria (table 1) have been the diagnostic 
tool for ARF for nearly 80 years.5 This is a regularly 
reviewed clinical algorithm, now available in a user- 
friendly smart device application (‘app’),6 most recently 
modified to optimise sensitivity for use in high- risk settings 
and optimise specificity for low- risk populations.7 Despite 
these revisions, ARF diagnosis remains challenging and 
subjective. Diagnostic biomarkers for ARF that improve 
the performance of these criteria or provide a definitive 
diagnostic test would be a major advance in improving 
ARF detection, and thereby, RHD prevention.8 Accurate 
case ascertainment is also needed to monitor progress 
towards disease control targets.
A further barrier to ARF management is the absence 
of an identified effective immunomodulatory treatment 
to alter long- term cardiac outcomes. Non- steroidal anti- 
inflammatory drugs alleviate joint symptoms but do not 
alter the long- term disease trajectory. Corticosteroids 
Table 1 Revised Jones criteria
High- risk groups* Low- risk groups
Definite initial episode of ARF 2 major manifestations+evidence of preceding GAS infection.
1 major +2 minor manifestations+evidence of preceding GAS infection.†
Definite recurrent‡ episode of ARF in 
a patient with a documented history of 
ARF or RHD
2 major manifestations+evidence of preceding GAS infection.
1 major +2 minor manifestations+evidence of preceding GAS infection.
3 minor manifestations+evidence of a preceding GAS infection.†
Probable or possible ARF (first episode 
or recurrence‡)
A clinical presentation in which ARF is considered a likely diagnosis but falls short in 
meeting the criteria by either:
 ► one major or one minor manifestation.
 ► no evidence of preceding GAS infection (streptococcal titres within normal limits or 
titres not measured).
Such cases should be further categorised according to the level of confidence with 
which the diagnosis is made:
 ► Probable ARF (previously termed ‘probable: highly suspected’).
 ► Possible ARF (previously termed ‘probable: uncertain’).
Major manifestations Carditis (including subclinical evidence of 
rheumatic valvulitis on echocardiogram)





Carditis (including subclinical evidence of 





Minor manifestations Fever ††≥38°C
Monoarthralgia ‡‡
ESR ≥30 mm/h or CRP ≥30 mg/L
Prolonged P- R interval on ECG§§
Fever ≥38.5°C
Polyarthralgia or aseptic monarthritis‡‡
ESR ≥60 mm/h or CRP ≥30 mg/L
Prolonged P- R interval on ECG§§
Reproduced with permission from The 2020 Australian guideline for prevention, diagnosis and management of ARF and RHD (third edition).2
*High- risk groups are those living in communities with high rates of ARF (incidence >30/100 000 per year in 5–14 years old) or RHD (all- age 
prevalence >2/1000). Aboriginal and Torres Strait Islander peoples living in rural or remote settings are known to be at high risk. Data are 
not available for other populations but Aboriginal and Torres Strait Islander peoples living in urban settings, Māori and Pacific Islanders, and 
potentially immigrants from developing countries, may also be at high risk.
†Elevated or rising antistreptolysin O or other streptococcal antibody, or a positive throat culture or rapid antigen or nucleic acid test for GAS 
infection.
‡Recurrent definite, probable or possible ARF requires a time period of more than 90 days after the onset of symptoms from the previous 
episode of definite, probable or possible ARF.
§A definite history of arthritis is sufficient to satisfy this manifestation. Note that if polyarthritis is present as a major manifestation, 
polyarthralgia or aseptic monarthritis cannot be considered an additional minor manifestation in the same person.
¶Chorea does not require other manifestations or evidence of preceding GAS infection, provided other causes of chorea are excluded.
**Care should be taken not to label other rashes, particularly non- specific viral exanthems, as erythema marginatum.
††In high- risk groups, fever can be considered a minor manifestation based on a reliable history (in the absence of documented temperature) 
if anti- inflammatory medication has already been administered.
‡‡If polyarthritis is present as a major criterion, monarthritis or arthralgia cannot be considered an additional minor manifestation.
§§If carditis is present as a major manifestation, a prolonged P- R interval cannot be considered an additional minor manifestation.
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appear ineffective in limiting development or severity 
of RHD,9 but in some settings are prescribed as a treat-
ment of last resort for severe carditis.10 11 Hydroxychlo-
roquine use has recently been reported in two cases of 
ARF with carditis, based on plausible in vitro data12 but 
efficacy is as yet unknown.13 Improved knowledge of 
ARF immune pathogenesis is needed to inform potential 
immune modulatory strategies targeted to the immune 
pathology. Compounding complexity, different patho-
logical processes may occur, accounting for the hetero-
geneous clinical phenotypes of ARF (table 1, see major 
manifestations).
Most investigations into the immune basis of ARF have 
used biased (directed) approaches, with limited utility. For 
example, elevated tumour necrosis factor-α, interleukin 6 
(IL-6) and IL-8 have been reported in patients with active 
ARF and RHD, but are unreliable disease markers.14–16 In 
difficult- to- diagnose diseases, the use of a multiplicity of 
biomarkers (‘multivariate’) to identify the presence or 
progression of disease has proven useful. Using microar-
rays, characteristic gene expression signatures have been 
reported in white blood cells from patients with Kawa-
saki disease (another inflammatory cardiac condition), 
lupus and tuberculosis demonstrating that multivariate 
expression profiling has potential to identify biomarker 
composite signatures as diagnostic tools.17–20 Multivariate 
approaches to analysing biomarkers in sera or plasma 
have also shown promise. In a bead- based multiplex assay, 
a number of Mycobacterium tuberculosis- reactive antibodies 
were successfully used to diagnose tuberculosis in non- 
human primates,21 and antibody glycosylation patterns 
can discriminate latent from active TB in humans.22 Most 
importantly, our recent studies show proof- of- principle 
for immunopathogenesis studies to understand ARF, 
identifying a dysregulated cytokine axis using multivariate 
approaches including RNAseq and flow cytometry12 as 
well as a linked IgG3- C4 response in early ARF with multi-
plex bead- based assays.23 Serumborne and plasmaborne 
biomarkers in addition to transcriptional profiling and 
circulating cellular components thus constitute a strong 
and accessible means of diagnosis once useful biomarkers 
have been identified.
Our hypothesis is that unbiased, multivariate analyses 
hold the greatest potential for identifying meaningful, 
translatable information on the immunopathogenesis 
of ARF. The aims of the ‘Searching for a Technology- 
Driven Acute Rheumatic Fever Test’ (START) study 
are to determine whether this approach can identify a 
biomarker signature that accurately classifies ARF diag-
noses according to a defined ‘gold- standard’ diagnosis 
(the 2015 revised Jones criteria applied by a panel of 
clinical experts), and to better understand ARF immune 
pathogenesis (table 2). Specifically, we aim to develop, 
in a discovery cohort and validate in a second cohort, a 
profile of metabolic and immunological biomarkers that 
distinguishes ARF cases from a range of non- ARF condi-
tions and healthy controls.
Table 2 Control groups
Group A (n=30): Non- ARF streptococcal infections or toxin mediated condition or poststreptococcal condition
Examples:
 ► Active infection with a proven or likely causative streptococcal organism (eg, β-haemolytic 
streptococcus, α-haemolytic streptococcus, S. pneumoniae etc) from sterile or non- sterile site.
 ► Scarlet fever.
 ► Acute poststreptococcal glomerulonephritis.
and
 ► No evidence of definite RHD on echocardiogram.
Group B (n=30): Other acute condition
Examples:
 ► Inflammatory conditions, including autoimmune inflammatory conditions (eg, lupus with arthritis), 
pancreatitis, etc.
 ► Infective condition: confirmed arboviral infection (eg, Ross River virus), septic arthritis, bacterial 
endocarditis, etc.
 ► Trauma requiring hospitalisation or operative procedure.
and
 ► No evidence of definite RHD on echocardiogram.
Group C (n=30): RHD
 ► Echocardiographically confirmed RHD with no active inflammation.
 ► History of definite ARF but no current disease activity.
Group D (n=30): Healthy
 ► No intercurrent medical condition as determined by clinical questionnaire.
 ► Minor trauma allowed.
and
 ► No evidence of definite RHD on echocardiogram.
ARF, acute rheumatic fever; RHD, rheumatic heart disease.
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START is a cross- national, prospective, observational 
study with a quasi case–control design. We will prospec-
tively recruit children and young adults with ARF, and 
people matched on age, sex and ethnicity who have 
eligible control diagnoses, in Australia and NZ. The study 
will comprise a discovery cohort (up to 65 definite cases 
and 65 controls) and a validation cohort (up to 25 defi-
nite cases and 65 controls). Probable and possible ARF 
diagnoses will then be tested independently (figure 1). 
Eligible control conditions are shown in table 2. Partic-
ipants will have blood collected for comprehensive 
immune profiling.
Ethics and dissemination
The study has approval from the NT Department of 
Health and Menzies School of Health Research ethics 
committee (18/3126) and the NZ Health and Disability 
Ethics Committee (18/CEN/197). It will be conducted 
according to Good Clinical Practice, Good Laboratory 
Practice and the National Health and Medical Research 
Council and ethical standards for research involving 
Indigenous Australians and NZ Māori and Pacific Peoples.
Knowledge dissemination will be through academic 
channels and community discussion forums. The study 
team is well placed to foster translation of findings into 
practical tools, namely, an improved diagnostic and 
immunomodulatory therapy.
Study sites
Participating hospitals across the two international 
sites: Royal Darwin Hospital, Darwin, NT, Australia, 
and Starship and Middlemore Hospitals, Auckland, NZ. 
Clinical guidelines at all three study sites require that 
all people with suspected ARF are hospitalised for diag-
nostic workup and initiation of management.10 24 Royal 
Darwin Hospital is the major tertiary referral hospital in 
Australia’s NT. Thirty per cent of the NT population is 
Indigenous (Aboriginal or Torres Strait Islander).25 ARF 
occurs at rates >300/100 000 total Aboriginal population 
in highest- burden communities in the NT.26 Starship and 
Middlemore Hospitals serve a combined urban popula-
tion of approximately 1.1 million people in the Auckland 
region. Māori and Pacific peoples make up approximately 
27% of the population of greater Auckland region, where 
the incidence of ARF among Māori and Pacific children is 
approximately 33/100 000 and 93/100 000, respectively, 
for those 5–15 years old.24 27
Study participants
Inclusion criteria for ARF cases are: individuals with 
suspected or confirmed ARF (the vast majority of whom 
are expected to identify as being of Aboriginal, Torres 
Figure 1 Study diagram showing target sample sizes. ARF, acute rheumatic fever; RHD, rheumatic heart disease.
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Strait Islander, Māori or Pacific ethnicity) aged 5–30 years 
(Darwin) or 2–20 years (NZ). Written, informed consent 
will be obtained from guardians or the participant them-
self if aged ≥16 years in NZ or ≥18 years in Australia. 
Differences between sites are consistent with local epio-
demiology and local ethical recommendations.
Exclusion criteria comprise individuals with severe 
anaemia in whom collection of the blood volume 
required for the study collection would be relatively 
contraindicated; profound immunosuppression other 
than corticosteroids for 2 months prior to study entry, or 
as appropriate depending on the half- life of the immuno-
suppressive agent and unstable social situation precluding 
discussion about consent for research.
Controls are recruited into one of four groups: (A) 
non- ARF Streptococcal infections; (B) other non- ARF 
acute inflammatory presentations; (C) established RHD 
without an intercurrent acute diagnosis and (D) healthy 
individuals (table 2). All must meet the above- stated age, 
ethnicity and consent inclusion criteria and none of the 
exclusion criteria. Controls will be matched at data anal-
ysis stage to cases by site on sex, age within 10 years, and 
ethnicity. Individuals in groups A, B and D will have an 
echocardiogram to exclude underlying RHD.
Cultural safety
Cultural safety28 is a core underpinning principle of the 
study. In NZ, the research is conducted in accordance 
with core Te Tiriti o Waitangi principles affording protec-
tion, participation and partnership for Māori partici-
pants. Research staff enrolling participants will engage 
appropriate family members (in NZ: whānau) and respect 
differences in decision- making processes. Interpreters 
and translated participant materials will be used where 
study participants and their families primarily speak 
another language. In Darwin, patient information has 
been recorded in six Aboriginal languages. In NZ, partic-
ipant materials have been translated into Te Reo Māori, 
Samoan and Tongan.
Patient and public involvement
The Indigenous investigators and collaborators at each 
site form governance groups to provide oversight of study 
design, conduct, reporting and dissemination. Patient and 
public involvement, drawing on our established consumer 
networks, will support knowledge dissemination.
Enrolment
It will be made clear that participation is voluntary and 
any benefits of participation are to society through 
knowledge advancement, rather than to the individual. 
Participants will be advised that wherever possible, blood 
collection for the study will coincide with collection done 
for clinical purposes, to avoid extravenipuncture. If a 
participant or their parent/guardian withdraws consent, 
no further samples will be collected unless a new consent 
form is signed. Participants are asked whether their blood 
may be stored for future use.
People with suspected ARF will be enrolled as early as 
possible during admission, prior to a final diagnosis being 
assigned, to ensure that an acute sample is collected. A 
final diagnosis will be assigned once all required diag-
nostic information has become available. Participants in 
group C (RHD) may additionally be recruited through 
outpatient clinics. Group D (healthy) will be sought from 
among family members and friends of other enrolled 
participants, or healthy members of the community in 
Darwin.
Clinical data collection
After assigning a sequential study code, clinical details 
will be recorded on a paper case report form (CRF) then 
entered into an electronic database (Medrio Electronic 
Data Capture System), including: date of illness onset, 
date of blood sample collection, demographics, clinical 
presentation, Jones criteria, clinical laboratory results, 
medications received and diagnosis assigned by the clin-
ical treating team.
Assignment of diagnosis
Patients presenting with suspected ARF may have a final 
diagnosis of definite ARF, probable ARF, possible ARF or 
a non- ARF condition. Probable ARF is defined in Austra-
lian guidelines as an acute presentation not fulfilling 
criteria, missing a major or minor criterion or lacking 
evidence of preceding streptococcal infection, but ARF 
is still considered the most likely diagnosis. Possible ARF 
applies to the same presentation type, but where ARF is 
considered uncertain but cannot be ruled out.10 For this 
study, participants ultimately diagnosed with a non- ARF 
condition will be allocated by the clinical panel as group 
A or B controls.
Management will be directed by treating clinicians. 
Clinical diagnoses will be assigned according to local 
Australian and NZ Diagnostic Criteria by a panel of ≥2 
study clinicians expert in ARF. The decision on diag-
nostic category requires clinical judgement, after evalu-
ating all aspects of the case. The Jones criteria app6 which 
provides a result of definite, probable or possible ARF 
or not ARF depending on information provided to the 
algorithm, will be used by the panel at their discretion. 
The diagnosis of carditis will be made if rheumatic valvu-
litis is evident on echocardiogram as per Jones criteria. 
The diagnosis of RHD will be made in accordance with 
features described by the World Heart Federation.29 The 
2015 revised Jones Criteria7 30 will be applied as the gold 
standard diagnostic for definite ARF. This represents a 
departure from normal practice in NZ where local diag-
nostic criteria differ: polyarthralgia is not considered a 
major criterion in NZ.24 In addition to the Jones criteria, 
comprehensive clinical and laboratory information, such 
as results of synovial fluid testing, serology for alterna-
tive infectious aetiologies, autoantibodies, radiological 
findings, diagnosis assigned by the treating team, family 
history and local epidemiology, will be considered in adju-
dicating the diagnosis. ARF type will be further specified 
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as initial episode or recurrence. Where the adjudication 
panel’s diagnosis differs from that of the treating team 
with implications for management, this will be communi-
cated to the treating specialist. The clinical panel will also 
assign final diagnoses for controls.
Blood collection
Blood will be collected at baseline, and for patients with 
ARF, on follow- up occasions during the convalescent 
period as able, for example, during prolonged hospital-
isation or at a later outpatient appointment (table 3). 
A safe maximum volume of 28.5 mL depending on age 
will be obtained in Australia,31 and 14.5 mL in NZ. Base-
line samples will be collected as soon as possible during 
the acute presentation, timed to coincide with routine 
blood testing wherever possible. Convalescent samples 
will be used to determine persistence and decay of immu-
nopathological signatures post ARF. After collection, 
samples will be transported immediately to research labo-
ratories at Menzies School of Health Research (Australia) 
or the University of Auckland (NZ) for centrifugation, 
serum/plasma separation and viable peripheral blood 
mononuclear cell (PBMC) preparation. Timely freezing 
and storage of serum/plasma aliquots, PAXgene tubes at 
−80°C and PBMCs in gas- phase liquid nitrogen. Samples 
will be shipped periodically to relevant laboratories.
Sample size
It is not possible to predict a priori the combined discrim-
inatory ability of independently measured factors. 
This study has elected to enrol up to 120 ARF cases 
(comprising approximately 90 definite ARF, 15 prob-
able, 15 possible) and 130 controls (30 each of control 
groups A, B and C, and 40 control group D; figure 1 and 
table 2). These numbers are feasible and should enable 
characterisation of different ARF clinical phenotypes 
(carditis, arthritis, chorea, skin/soft- tissue manifestations 
or a combination of these) and phases (first or recurrent 
episodes), acknowledging heterogeneity among partic-
ipants (ethnicity, age, sex; on corticosteroids or not; at 
different stages of illness).
In the multivariate approach, it is expected that most, 
if not all, of the influential factors in the optimal model 
will be significant (p<0.05) in univariate testing. Assuming 
α of 5% and 95% power (β=0.05) the minimum sample 
size is 26 cases. These calculations are only a guideline for 
removing clear false positives, as the standard procedure 
for producing robust screening models is to have a sepa-
rate blinded analysis of a test subset of samples. We will 
use discovery and validation cohorts, together with strati-
fied bootstrap cross- validation to internally optimise the 
structural parameters in each model. We further used the 
standard inferential approach to sample size estimation in 
diagnostic test studies of biomedical informatics.32 An effec-
tive multivariate predictor of ARF with positive predictive 
value of 0.8 (clinically useful), and a 95% CI of±0.1, would 
require 65 ARF cases in the discovery cohort.
The discovery cohort will, therefore, comprise a target 
of 65 definite ARF cases and 65 controls. The validation 
cohort will comprise a target of 25 definite ARF cases and 
65 controls. Probable and possible diagnoses (~15 in each 
group) will be tested independently (figure 1). Cases will 
be allocated to the discovery or validation cohorts using 
a computer- generated random selection of unique study 
identification numbers.
Laboratory methods
The overarching aim is to develop and validate a profile 
of host related biomarkers that distinguishes ARF cases 
from non- ARF conditions and healthy controls. This will 
be achieved through the following analyses on peripheral 
blood samples.
Immunophenotyping
PBMC will be stained with labelled antibody panels to 
identify specific cell populations. Flow cytometry raw 
Table 3 Blood collection
Australian recruitment site
  Participant age Collection tube
Testing procedures 5–9 years ≥10 years   
Transcriptional profiling 2.5 mL 2.5 mL PaxGene tube
Peripheral blood mononuclear cells for flow cytometry, metabolomics 4.0 mL 22.0 mL Sodium heparin
Antibody studies 4.0 mL 4.0 mL Serum
Total 10.5 mL 28.5 mL   
  New Zealand recruitment sites
  Participant age Collection tube
Testing procedures 2–10 years ≥11 years   
Transcriptional profiling 2.5 mL 2.5 mL PaxGene tube
Peripheral blood mononuclear cells for flow cytometry, metabolomics 4.0 mL 8.0 mL Sodium heparin
Antibody studies 4.0 mL 4.0 mL Serum
Total 10.5 mL 14.5 mL   
copyright.
 on O













pen: first published as 10.1136/bm






7Ralph AP, et al. BMJ Open 2021;11:e053720. doi:10.1136/bmjopen-2021-053720
Open access
data will be analysed manually using Flowjo software and 
via an automated gating platform as described.33 34 Such 
high throughput, automated analysis of big flow cytom-
etry data offers several advantages over manual gating, 
including increased throughput while increasing quality 
control (such as preprocessing removal of anomalous 
events via the flowCut algorithm), and identification of 
specific cell populations with up to 50- dimensional data-
sets.34–36 Plasma samples will be analysed using multi-
plex cytokine assays to quantify cytokine and chemokine 
plasma concentrations, detailed elsewhere.33 37–39
Metabolome analyses
Untargeted metabolomic profiling (>1000 metabolites) 
will be performed on plasma samples using liquid chroma-
tography coupled to high- resolution mass- spectrometry 
(LC- MS). Data will be acquired using three modes of 
operation: reverse- phase/ultraperformance liquid chro-
matography (UPLC)- MS/MS with positive ion mode 
electrospray ionisation (ESI), reverse- phase/UPLC- MS/
MS with negative ion mode ESI, and Hydrophilic inter-
action (HILIC)/UPLC- MS/MS with negative ion mode 
ESI. All identified metabolites will be annotated using 
appropriate orthogonal analytical techniques applied to 
the metabolite of interest against a chemical reference 
standard.
Blood transcriptomics
RNA will be extracted from stabilised whole blood samples 
(PAXgene tubes) as described,40 41 libraries prepared 
(TruSeq Stranded Total RNA with Ribo- Zero Globin 
reduction, Illumina) and NextGen sequencing under-
taken (Illumina HiSeq2500, 50 bp single- end reads). Read 
alignment and gene- level quantification (counts) will be 
performed using Hisat.42 Negative binomial models will 
be employed for differential expression analysis, with false 
discovery rate control for multiple testing.43 The analyses 
will be adjusted for batch effects and variations in cellular 
composition, which will be estimated employing Remove 
Unwanted Variation from RNA- Seq Data (RUVSeq) and 
CIBERSORT, respectively.44 45 Genes will be mapped to 
blood transcriptional modules to provide a systems- level 
view of the responses and reduce the dimensionality of 
the data.46
CD4 T cell transcriptomic responses to GAS
A two- phased approach will be used to examine CD4 T 
cell responses to GAS. First, PBMCs from a subset of defi-
nite ARF cases and healthy controls will be cultured under 
a variety of conditions to identify optimal conditions for 
the second phase. Cells will be harvested at multiple time 
points poststimulation (6 hours, 24 hours and 48 hours) 
with heat- killed and antibiotic- killed ARF- associated GAS 
strains12 47 48 and a selection of candidate ARF antigens. 
Total RNA from PBMCs cultured under each condition 
will be profiled by RNA- Seq (Illumina 100 bp paired- end 
reads, 20M reads), and culture supernatants will be 
examined by Luminex (Bio- Plex 48- plex Pro Human 
Cytokine Screening Panel) to identify optimal condi-
tions for maximal discrimination of responses between 
cases and controls. In the second phase, an expanded set 
of ARF cases and controls for which PBMC samples are 
available will be examined following culture under the 
identified, optimal conditions. Gene expression patterns 
and cytokine production will be profiled by RNA- Seq and 
Luminex, as described above.
Antibody analysis
For unbiased investigation of autoantibodies, selected 
sera will be screened against planer protein microar-
rays comprised of over 42 000 protein fragments repre-
senting some 19 000 human proteins.49 Protein fragments 
that are more significantly bound by autoantibodies 
in ARF compared with controls will be identified using 
a  >0.05 and fold change of 2.0 as cut- off. A suspension 
bead array will then be designed50 composed of up to 380 
potential autoantigens to assess autoantigen reactivity in 
all sera. The bead- antigens will be selected based on the 
planar array results, previously completed screens using 
high- content protein arrays,51 and targets from the liter-
ature. Finally, candidate ARF autoantigens identified in 
the suspension bead- array will be orthogonally validated 
as individual antigens in ELISA or Luminex bead- based 
assays to determine sensitivity and specificity.
Bioinformatics and statistical analyses
The data collected for each patient across the immune 
phenotyping, transcriptomic, proteomic and metabo-
lomic technologies will be integrated computationally 
to identify patterns of covariance within and between 
designated clinical outcome groups. Convergence of 
signatures across diverse systems biology domains will 
provide independent functional validation. The use of 
‘multiomic’ data integration techniques will also enable 
the possibility of deriving novel biological information 
that will not be revealed in a single dataset alone.
Data integration methods applying different computa-
tional strategies will be used to explore the complex cova-
riance structure within and between the multiomic data 
blocks. Initially, analysis will focus on each data block in 
isolation employing a combination of classical generalised 
linear modelling, multivariate projection regression 
models (Principal Component Analysis (PCA), Partial 
Least Squares Discriminant Analysis (PLS- DA)) and unsu-
pervised cluster analysis. The multiple blocks will then be 
integrated into a single computational model to enable 
multiomic functional mapping, which in turn will allow 
us to uncover the underlying biochemical mechanisms. 
Several methods for performing multiblock data integra-
tion will be investigated, from which a consensus model 
will be derived. These will include: protein−protein 
interaction networks using NetworkAnalyst,52 Multiblock 
component analysis,53 regularised canonical correlation 
analysis,54 the Data Integration Analysis for Biomarker 
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This systems biology analysis should result in both a 
domain- specific and domain- integrative summary of 
biological phenomena that are associated with clinical 
outcome. Likely outcomes are a signature biological 
pathway associated with ARF as well as individual candi-
date markers that may provide the basis for the devel-
opment of novel diagnostic tests. Furthermore, the data 
generated through this effort will allow crisply defined 
power calculations for future narrowly targeted assess-
ment of potential biomarkers in clinical trials.
DISCUSSION
We anticipate that study findings will provide the most 
comprehensive knowledge of the immunopathogenesis 
of ARF to date, be used as the basis for development of 
a diagnostic test and provide a pathway towards devel-
opment of targeted immunomodulatory treatment(s). 
START commenced recruitment in Australia in November 
2018 and in NZ in May 2019. Anticipated completion 
of recruitment is end-2021. Laboratory analyses will be 
batched and run together at completion of recruitment.
Both underdiagnosisand overdiagnosis of ARF pose 
major challenges to individuals and health systems.10 
Whether the use of the ‘probable’ and ‘possible’ ARF 
diagnostic categories is reducing underdiagnosis or 
contributing to overdiagnosis is currently unknown. 
Should findings from this study successfully identify a 
discriminatory biomarker profile differentiating definite 
ARF from non- ARF, this will provide a mechanism for 
accurate diagnosis to guide appropriate management. 
This will be a critically important advance in the diagnosis 
and management of ARF globally.
A minority of any population are at risk of ARF after 
exposure to group A streptococci. The estimated lifetime 
cumulative incidence of ARF was previously calculated at 
5.7% in Australia’s NT.57 This was considered likely to be 
an underestimate, and indeed more recent data highlight 
the burden of unrecognised ARF in Aboriginal commu-
nities in the NT where repeated infection with GAS is 
ubiquitous from early childhood,2 58 suggesting that the 
lifetime risk of ARF in these populations is higher than 
6%. In US military camps, 2%–3% of recruits developed 
ARF after a single bout of streptococcal pharyngitis.59
Previous efforts to develop ARF diagnostic tests and 
elucidate the immunopathogenesis have laid founda-
tions for the START study design and analysis. Kim et al12 
analysed responses to GAS challenge of PBMC from ARF 
patients at Royal Darwin Hospital using multiplex cytokine 
array, flow cytometric analysis and global gene expression 
analysis by RNA sequencing. They identified a dysregu-
lated IL-1β-granulocyte- macrophage colony- stimulating 
factor cytokine axis in PBMCs from ARF patients, and 
the potential to suppress this response by hydroxychloro-
quine. The authors proposed that hydroxychloroquine, 
an immunomodulatory agent, could be repurposed to 
reduce the risk or severity of RHD after ARF.12 Clinical 
use of hydroxychloroquine, now reported as safe in two 
cases,13 requires further investigation. A study using sera 
from patients with ARF in NZ combined multiplex bead- 
based assays and systems immunology data analysis to 
identify a linked IgG3- C4 response that may have utility 
as a clinical biomarker in early ARF.23 However, small 
sample sizes have been a limiting factor. Key strengths of 
the current study include the larger sample size, multi-
centre enrolment across different countries to maximise 
relevance and use of the latest laboratory approaches.
Limitations include that capture of eligible participants 
early in disease is challenging, due to the variable time 
taken for participants to be hospitalised after disease 
onset, to identify and gain consent from participants, and 
obtain blood samples. At the Australian site, the majority 
of eligible participants will be Aboriginal children living 
in remote communities, often hundreds of kilometres 
distant from the enrolment site. Although Auckland is 
a large urban city inequitable healthcare access is expe-
rienced by many Māori and Pacific people living in 
socioeconomic deprivation and this can lead to delayed 
hospitalisation for many children presenting with ARF. 
Given these inherent delays, a proportion of baseline 
blood samples will be collected after the peak inflamma-
tory phase has passed. Another limitation is heterogeneity 
among people with ARF with regards to ARF type (first or 
recurrent), diagnostic category (possible, probable, defi-
nite), clinical phenotype (carditis, chorea, arthritis, etc) 
and demographic variations; however, we limited enrol-
ment to people below 30 years and only of Aboriginal, 
Torres Strait Islander, Māori or Pacific ethnicity to mini-
mise heterogeneity. Although a distinguishing biomarker 
signature may be identified, the ability to readily translate 
study findings into a feasible diagnostic able to be used 
in health service laboratories outside a research environ-
ment, is uncertain.
Successful completion of this study will considerably 
improve knowledge of ARF immunology. Innovative strat-
egies to improve the clinical management of ARF are 
core components of the overall suite of activities required 
to achieve the goal of RHD elimination.60
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